Article

Development of a novel ovarian cancer molecular target therapy against cancer-related transcriptional factor, NAC1

Departments of Obstetrics and Gynecology Biocehmistory, Shimane University School of Medicine, Izumo, Japan.
Journal of Obstetrics and Gynaecology Research (Impact Factor: 0.93). 07/2012; 39(1). DOI: 10.1111/j.1447-0756.2012.01946.x
Source: PubMed
0 Followers
 · 
8 Reads
  • Source
    • "NAC1 inhibitors therefore may not only induce cell death but also suppress the metastasis of ovarian cancer cells. To this effect, we are presently researching agents that inhibit NAC1 [27]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ovarian cancer is the most lethal gynecologic malignancy. Despite advances in chemotherapy, the five-year survival rate of advanced ovarian cancer patients with peritoneal metastasis remains around 30%. The most significant prognostic factor is stage, and most patients present at an advanced stage with peritoneal dissemination. There is often no clearly identifiable precursor lesion; therefore, the events leading to metastatic disease are poorly understood. This article reviews metastatic suppressor genes, the epithelial-mesenchymal transition (EMT), and the tumor microenvironment as they relate to ovarian cancer metastasis. Additionally, novel chemotherapeutic agents targeting the metastasis-related biochemical pathways are discussed.
    Full-text · Article · Dec 2012 · International Journal of Molecular Sciences
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to explore the role of miR-339-5p in ovarian cancer. The expression of miR-339-5p in seven ovarian cancer cell lines (Hey, SKOV3, OVCAR5, SKOV3-IP, A2780, CAOV3, and OVCA433) was detected by quantitative real-time polymerase chain reaction (qRT-PCR). The miR-339-5p mimic and inhibitor were used to regulate its expression. Migration, invasion, and proliferation were examined. A bioinformatics analysis was used to predict targets, and a dual-luciferase reporter system was applied for validation, along with Western blot verification. Additionally, the association of miR-339-5p and its target genes with ovarian cancer was analyzed based on The Cancer Genome Atlas (TCGA) database. OVCAR5 and SKOV3 had the highest and lowest miR-339-5p expression, respectively. Inhibition of miR-339-5p expression increased the migration and invasion of OVCAR5 cells, while in SKOV3 cells, upregulated miR-339-5p attenuated the migration and invasion ability. Modulation of miR-339-5p had no effect on proliferation. The genes nucleus accumbens associated 1(BEN and BTB (POZ) domain containing) (NACC1) and B cell lymphoma-6 (bcl6) were validated to be targets of miR-339-5p. Clinically, patients with a high expression of NACC1 had a high risk in the survival analysis. miR-339-5p inhibits migration and invasion in ovarian cancer by targeting NACC1 and BCL6. miR-339-5p may be a biomarker of metastasis in ovarian cancer; NACC1 had a predictive value for ovarian cancer progression.
    No preview · Article · Nov 2015 · Tumor Biology